Allogene Therapeutics Inc Financial Flexibility Index
Allogene Therapeutics Inc financial flexibility index. Allogene Therapeutics Inc (ALLO) has a Financial Flexibility Index of -0.24x as of September 2025. Free cash flow of $-29.45 Million (operating CF $-29.69 Million minus capex $243.00K) represents 0% of total liabilities ($124.44 Million). See ALLO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Allogene Therapeutics Inc (2017–2024)
Financial flexibility index of Allogene Therapeutics Inc from 2017 to 2024. Historical Financial Flexibility Index trend for Allogene Therapeutics Inc across 8 annual periods. Explore Allogene Therapeutics Inc (ALLO) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Allogene Therapeutics Inc Financial Flexibility Index by Year (2017–2024)
Allogene Therapeutics Inc financial flexibility index by year from 2017 to 2024. Year-by-year free cash flow to debt coverage for Allogene Therapeutics Inc. For the full cash flow conversion analysis, see ALLO operating cash flow.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.58x | $-199.61 Million | $-200.30 Million | $126.53 Million | ▲ +12.8% |
| 2023 | -1.81x | $-236.22 Million | $-237.73 Million | $130.60 Million | ▼ -29.9% |
| 2022 | -1.39x | $-215.33 Million | $-220.52 Million | $154.70 Million | ▼ -7.0% |
| 2021 | -1.30x | $-163.37 Million | $-184.81 Million | $125.63 Million | ▼ -292.3% |
| 2020 | -0.33x | $-49.13 Million | $-115.09 Million | $148.21 Million | ▲ +66.0% |
| 2019 | -0.97x | $-86.56 Million | $-137.35 Million | $88.78 Million | ▼ -66.4% |
| 2018 | -0.59x | $-41.42 Million | $-44.65 Million | $70.69 Million | ▲ +100.0% |
| 2017 | -19660.50x | $-39.32 Million | $-44.65 Million | $2.00K | — |